CTMX — CytomX Therapeutics Balance Sheet
0.000.00%
- $64.66m
- -$35.96m
- $138.10m
- 32
- 99
- 67
- 73
Annual balance sheet for CytomX Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K/A | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | — |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 316 | 305 | 194 | 175 | 101 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.798 | 0.79 | 36 | 3.43 | 3.1 |
Prepaid Expenses | |||||
Total Current Assets | 324 | 310 | 237 | 183 | 107 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 29.4 | 25.3 | 21 | 16.2 | 10.6 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 359 | 339 | 261 | 202 | 121 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 101 | 77.9 | 153 | 156 | 85.8 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 309 | 340 | 347 | 249 | 121 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 49.8 | -0.459 | -85.8 | -47.4 | -0.456 |
Total Liabilities & Shareholders' Equity | 359 | 339 | 261 | 202 | 121 |
Total Common Shares Outstanding |